Autosomal dominant polycystic kidney disease (ADPKD), which is characterized by marked phenotypic variability, is caused by mutation to PKD1 or PKD2. Understanding factors that underlie this variability is of diagnostic, prognostic and mechanistic importance. During the past funding period we have improved mutation detection levels from ~70-90% by employing direct sequencing, evaluation of non-definite variants for pathogenicity, and screening for larger rearrangements. The remaining ~10% of cases will be a major focus of Aim 1 of this proposal to understand the etiology of disease. Areas that will be explored are: atypical mutations to regulatory regions, including potential miRNA binding sites;cryptic splicing;mosaicism;gene conversion to PKD1;and further genetic heterogeneity. A group of ~170 families without detected conventional PKD1 or PKD2 mutations will be available, as well as access to putative unlinked families. A major finding from the previous study period was that incompletely penetrant (hypomorphic) PKD1 alleles underlie some of the phenotypic variability in ADPKD. Alone they can be responsible for mild PKD1, while as homozygotes or compound heterozygotes (including in trans with an inactivating allele), can result in early-onset disease. The full role of these incompletely penetrant alleles will be analyzed here be determining their frequency in populations with either later or early-onset ADPKD (Aim 2). How these alleles exert an effect will be analyzed at the cellular level. To fully prove their significance and test the mode of action, knock-in mouse models of two variants will be generated. The role of the alleles in modulating the phenotype of the whole animal will be tested and by combining alleles (including with existing null alleles) models with different disease severities will be generated;suitable for therapeutic testing. Expression of the hypomorphic alleles at the mRNA and protein level will be assayed, and the cellular consequences assessed. The last aim will explore next-generation sequencing methods to improve mutation screening of ADPKD. Protocols will be developed to further analyze the mutation negative patient group, specifically looking for changes missed by the existing locus-specific analysis of PKD1 and conventional sequencing. Finally, a more comprehensive screening protocol including related disease genes and potential modifier loci will be developed for ADPKD diagnostic/prognostic screening. The proposed studies should, overall, reveal more about mechanisms of mutation causing ADPKD, including the significance of further genetic heterogeneity and hypomorphic alleles, and result in a much more comprehensive screening protocol.

Public Health Relevance

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease and an important cause of renal failure;patients requiring transplantation or dialysis. The severity of disease differs considerably between patients and understanding factors underlying these differences would be of diagnostic and prognostic importance. Following up on advances from the last funding cycle, improved genetic screening will be employed to increase the level of positive diagnostic tests and further our understanding of the causes of ADPKD. The full significant of a novel class of mutations and the involvement of additional genes, will be explored. This will include mimicking these variants in an animal model. Finally, revolutionary new DNA characterization methods will be utilized. The results from this study will improve diagnostics and prognostics for ADPKD, plus provide a better animal model for testing potential therapies.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-DKUS-G (04))
Program Officer
Rasooly, Rebekah S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Paul, Binu M; Consugar, Mark B; Ryan Lee, Moonnoh et al. (2014) Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney Int 85:383-92
Torres, Vicente E; Harris, Peter C (2014) Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25:18-32
Harris, Peter C; Torres, Vicente E (2014) Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 124:2315-24
Vazifehmand, Reza; Rossetti, Sandro; Saber, Sassan et al. (2013) Molecular analysis of a consanguineous Iranian polycystic kidney disease family identifies a PKD2 mutation that aids diagnostics. BMC Nephrol 14:190
Paavola, Jere; Schliffke, Simon; Rossetti, Sandro et al. (2013) Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy. J Mol Cell Cardiol 58:199-208
Rossetti, Sandro; Harris, Peter C (2013) The genetics of vascular complications in autosomal dominant polycystic kidney disease (ADPKD). Curr Hypertens Rev 9:37-43
Harris, Peter C; Hopp, Katharina (2013) The mutation, a key determinant of phenotype in ADPKD. J Am Soc Nephrol 24:868-70
Herbert, Brittney-Shea; Grimes, Brenda R; Xu, Wei Min et al. (2013) A telomerase immortalized human proximal tubule cell line with a truncation mutation (Q4004X) in polycystin-1. PLoS One 8:e55191
Rossetti, Sandro; Hopp, Katharina; Sikkink, Robert A et al. (2012) Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 23:915-33
Mohney, Brian G; Pulido, Jose S; Lindor, Noralane M et al. (2011) A novel mutation of LAMB2 in a multigenerational mennonite family reveals a new phenotypic variant of Pierson syndrome. Ophthalmology 118:1137-44

Showing the most recent 10 out of 30 publications